Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the Canadian authorities issued a patent for the drug candidate CS1:s second patent family on Tuesday April 9. This strengthens and expands the immaterial rights (IPR) for Cereno’s drug candidate CS1, which is currently in clinical Phase II development as a treatment of the rare disease Pulmonary Arterial Hypertension (PAH).“I am pleased to announce that we have secured further immaterial rights for the drug candidate CS1 in